30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q12 and 2012 Revenue: NuVasive

$620.3MM, +15% (Ex-U.S. +45%)

  • U.S. Lumbar +5%
  • U.S. Cervical +15%
  • U.S. Biologics +8%
  • U.S. Intraoperative Monitoring $39MM

4Q12 revenue: $165.8MM, +10% (U.S. implants $111.7MM, +7%; ex-U.S. $14.8MM, +65%)

  • U.S. Lumbar +6%
  • U.S. Cervical +11%
  • U.S. Biologics $28.4MM, +6%
  • U.S. Intraoperative Monitoring $9.6MM, -1%
  • International (including Puerto Rico) represents ~10% of sales; Australia represents largest ex-U.S. market
  • Re-engaged salesforce with mobile resources (iPads), new asset management programs to increase inventory turnover, share case reviews (used to share info with surgeons following 1st PCM cervical disc case)
  • Received Shonin approval to sell posterior spinal fusion, XLIF implants in Japan
  • Renewed “NUVATouch” program to enlist executive team to consistently engage with top customers
  • Continuing rollout of Precept, multilevel percutaneous posterior MIS solution selling at premium price
  • Continued uncertainty on pending clearance of AttraX
  • Added 18 reps in 4Q, for total ~330; expecting to add 15-20 in 2013
  • Expects 2013 global spine growth to be flat, U.S. flat to down slightly, ex-U.S. up in high single digits
  • Estimates that PODs represent 15% of U.S. spine market